UnitedHealthcare initially denied coverage for Novartis’ drug Zolgensma, a one-time treatment for spinal muscular atrophy, but has since approved coverage for all six requests it received for the new drug.
The advanced gene treatment was approved by the FDA in May for most children under age 2 with spinal muscular atrophy. Insurers have been reluctant to cover new gene treatments based on medical necessity.
UnitedHealth Group’s CMO, Richard Migliori, MD, told The Washington Post the coverage reversals were based on clinical evidence, not on public attention generated by the denials.
Read more here.
More articles on payers:
UnitedHealth records $3.3B profit in Q2
Minnesota hospitals ask state to investigate BCBS over new policy ending coverage for 7 forms of routine care
New York insurer opens office in hospital
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
